Gilead Sciences Inc (GILD)

Return on equity (ROE)

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income (ttm) US$ in thousands 5,664,000 5,875,000 5,484,000 5,583,000 4,592,000 3,334,000 4,137,000 4,515,000 6,225,000 7,394,000 5,162,000 301,000 123,000 1,268,000 -257,000 4,962,000 5,386,000 2,693,000 5,955,000 5,892,000
Total stockholders’ equity US$ in thousands 22,833,000 22,314,000 21,158,000 20,997,000 21,240,000 21,081,000 20,236,000 19,927,000 21,069,000 21,470,000 19,703,000 18,952,000 18,202,000 17,445,000 18,027,000 22,067,000 22,525,000 20,604,000 22,616,000 21,951,000
ROE 24.81% 26.33% 25.92% 26.59% 21.62% 15.82% 20.44% 22.66% 29.55% 34.44% 26.20% 1.59% 0.68% 7.27% -1.43% 22.49% 23.91% 13.07% 26.33% 26.84%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $5,664,000K ÷ $22,833,000K
= 24.81%

The return on equity (ROE) of Gilead Sciences, Inc. has shown a consistent upward trend over the past eight quarters, reflecting the company's improving profitability and efficiency in generating returns for its shareholders. The ROE has ranged from a low of 15.82% in Q3 2022 to a high of 26.59% in Q1 2023. This indicates that for every dollar of equity invested by shareholders, the company is generating between 15.82 cents and 26.59 cents in net income.

The upward trend in ROE suggests that Gilead Sciences, Inc. is effectively utilizing its assets and shareholders' equity to generate profits. This could be attributed to efficient cost management, strong revenue growth, effective capital allocation, or a combination of these factors. The company's ability to consistently improve its ROE is a positive sign for investors, as it indicates a strong financial performance and a potential for higher returns on their investment in the company.


Peer comparison

Dec 31, 2023


See also:

Gilead Sciences Inc Return on Equity (ROE) (Quarterly Data)